XORTX Therapeutics Inc
XTSX:XRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Wuhan Zhongyuan Huadian Science & Technology Co Ltd
SZSE:300018
|
CN |
|
Aditya Birla Capital Ltd
NSE:ABCAPITAL
|
IN |
XORTX Therapeutics Inc
Long-Term Debt
XORTX Therapeutics Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XORTX Therapeutics Inc
XTSX:XRTX
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Long-Term Debt
$20.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Long-Term Debt
CA$242.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
52%
|
|
|
Cronos Group Inc
TSX:CRON
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Long-Term Debt
$40.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Long-Term Debt
CA$57.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
87%
|
CAGR 10-Years
N/A
|
|
XORTX Therapeutics Inc
Glance View
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
See Also
What is XORTX Therapeutics Inc's Long-Term Debt?
Long-Term Debt
0
USD
Based on the financial report for Dec 31, 2025, XORTX Therapeutics Inc's Long-Term Debt amounts to 0 USD.
